Symbols

Symbols

Aime

Products

News

Markets

Watchlist

Brokers

News/

Stock/

PDSB

PDSB News

Newswire

04:27

PDS Biotechnology shares surge 14.24% premarket after FDA accepts Type C Meeting to discuss accelerated approval pathway for PDS0101 in HPV16-positive cancer.

08:43

B. Riley Lowers PDS Biotechnology Price Target to $3, Keeps Buy Rating

13:16

B. Riley Securities maintains Buy on PDS Biotechnology, lowers PT to $3.

23:08

PDS Biotechnology Sees 693.73% Upside Potential, HC Wainwright Maintains Buy Recommendation

13:31

PDS Biotechnology: HC Wainwright raises Buy rating, PT to $15 from $13.

View More

About PDSB

Charts

--

Sector--

Established Date--

Listing Date--

Exchange--

Full-time Employees--

Fiscal Year Ends--

Website

Security Type--

Office address

Business

Introduction

View More